1.13 USD
-0.07 (-5.83%)
1.13 USD
0 (0%)
ZYBT gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of ZYBT get a neutral evaluation. Nothing too spectacular is happening here. ZYBT has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year ZYBT was profitable.
ZYBT had a positive operating cash flow in the past year.
1.2 Ratios
ZYBT has a better Return On Assets (7.96%) than 89.01% of its industry peers.
With an excellent Return On Equity value of 13.83%, ZYBT belongs to the best of the industry, outperforming 87.96% of the companies in the same industry.
With an excellent Return On Invested Capital value of 12.67%, ZYBT belongs to the best of the industry, outperforming 91.62% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for ZYBT is below the industry average of 12.85%.
The 3 year average ROIC (10.57%) for ZYBT is below the current ROIC(12.67%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| ROIC | 12.67% |
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 12.95%, ZYBT belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
In the last couple of years the Profit Margin of ZYBT has declined.
The Operating Margin of ZYBT (16.66%) is better than 86.39% of its industry peers.
ZYBT's Operating Margin has declined in the last couple of years.
ZYBT has a better Gross Margin (54.00%) than 65.44% of its industry peers.
ZYBT's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.66% | ||
| PM (TTM) | 12.95% | ||
| GM | 54% |
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ZYBT has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for ZYBT remains at a similar level compared to 1 year ago.
ZYBT has a better debt/assets ratio than last year.
2.2 Solvency
ZYBT has an Altman-Z score of 2.36. This is not the best score and indicates that ZYBT is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of ZYBT (2.36) is better than 62.30% of its industry peers.
The Debt to FCF ratio of ZYBT is 6.51, which is on the high side as it means it would take ZYBT, 6.51 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 6.51, ZYBT belongs to the top of the industry, outperforming 80.63% of the companies in the same industry.
ZYBT has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.02, ZYBT perfoms like the industry average, outperforming 54.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 6.51 | ||
| Altman-Z | 2.36 |
ROIC/WACC1.58
WACC8%
2.3 Liquidity
A Current Ratio of 1.31 indicates that ZYBT should not have too much problems paying its short term obligations.
ZYBT's Current ratio of 1.31 is on the low side compared to the rest of the industry. ZYBT is outperformed by 76.44% of its industry peers.
A Quick Ratio of 0.88 indicates that ZYBT may have some problems paying its short term obligations.
ZYBT has a worse Quick ratio (0.88) than 80.63% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.88 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.94% over the past year.
ZYBT shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 528.02% yearly.
Looking at the last year, ZYBT shows a very strong growth in Revenue. The Revenue has grown by 43.18%.
Measured over the past years, ZYBT shows a very strong growth in Revenue. The Revenue has been growing by 854.79% on average per year.
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ZYBT is valuated reasonably with a Price/Earnings ratio of 9.42.
91.62% of the companies in the same industry are more expensive than ZYBT, based on the Price/Earnings ratio.
ZYBT's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.42 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ZYBT indicates a rather cheap valuation: ZYBT is cheaper than 96.86% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, ZYBT is valued cheaper than 81.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.21 | ||
| EV/EBITDA | 5.89 |
4.3 Compensation for Growth
ZYBT has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ZYBT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.13
-0.07 (-5.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0.33%
Inst Owner ChangeN/A
Ins Owners6.53%
Ins Owner ChangeN/A
Market Cap53.55M
Revenue(TTM)303.21M
Net Income(TTM)39.27M
AnalystsN/A
Price TargetN/A
Short Float %0.74%
Short Ratio0.99
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly Dividend0.05
Dividend Growth(5Y)N/A
DP40.8%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 9.42 | ||
| Fwd PE | N/A | ||
| P/S | 1.24 | ||
| P/FCF | 28.21 | ||
| P/OCF | 9.12 | ||
| P/B | 1.32 | ||
| P/tB | 1.43 | ||
| EV/EBITDA | 5.89 |
EPS(TTM)0.12
EY10.62%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.04
FCFY3.54%
OCF(TTM)0.12
OCFY10.96%
SpS0.91
BVpS0.86
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Graham Number1.52
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.96% | ||
| ROE | 13.83% | ||
| ROCE | 14.13% | ||
| ROIC | 12.67% | ||
| ROICexc | 13.42% | ||
| ROICexgc | 14.4% | ||
| OM | 16.66% | ||
| PM (TTM) | 12.95% | ||
| GM | 54% | ||
| FCFM | 4.38% |
ROA(3y)5.86%
ROA(5y)N/A
ROE(3y)10.42%
ROE(5y)N/A
ROIC(3y)10.57%
ROIC(5y)N/A
ROICexc(3y)10.67%
ROICexc(5y)N/A
ROICexgc(3y)11.51%
ROICexgc(5y)N/A
ROCE(3y)11.8%
ROCE(5y)N/A
ROICexgc growth 3Y-33.64%
ROICexgc growth 5YN/A
ROICexc growth 3Y-34.32%
ROICexc growth 5YN/A
OM growth 3Y-29.5%
OM growth 5YN/A
PM growth 3Y-34.62%
PM growth 5YN/A
GM growth 3Y-5.78%
GM growth 5YN/A
F-Score7
Asset Turnover0.61
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 6.51 | ||
| Debt/EBITDA | 0.06 | ||
| Cap/Depr | 114.94% | ||
| Cap/Sales | 9.16% | ||
| Interest Coverage | 12.67 | ||
| Cash Conversion | 54.97% | ||
| Profit Quality | 33.8% | ||
| Current Ratio | 1.31 | ||
| Quick Ratio | 0.88 | ||
| Altman-Z | 2.36 |
F-Score7
WACC8%
ROIC/WACC1.58
Cap/Depr(3y)102.94%
Cap/Depr(5y)N/A
Cap/Sales(3y)10.29%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.94%
EPS 3Y528.02%
EPS 5YN/A
EPS Q2Q%-64.04%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)43.18%
Revenue growth 3Y854.79%
Revenue growth 5YN/A
Sales Q2Q%-11.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y12.17%
EBIT growth 3Y573.13%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-63.72%
FCF growth 3Y1249.56%
FCF growth 5YN/A
OCF growth 1Y-14.81%
OCF growth 3Y988.8%
OCF growth 5YN/A
ZHENGYE BIOTECHNOLOGY HOLDIN / ZYBT FAQ
What is the ChartMill fundamental rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) stock?
ChartMill assigns a fundamental rating of 5 / 10 to ZYBT.
Can you provide the valuation status for ZHENGYE BIOTECHNOLOGY HOLDIN?
ChartMill assigns a valuation rating of 5 / 10 to ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT). This can be considered as Fairly Valued.
What is the profitability of ZYBT stock?
ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) has a profitability rating of 6 / 10.
Can you provide the financial health for ZYBT stock?
The financial health rating of ZHENGYE BIOTECHNOLOGY HOLDIN (ZYBT) is 4 / 10.